Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Entrada Therapeutics (TRDA) Change in Accured Expenses (2022 - 2025)

Historic Change in Accured Expenses for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $3.7 million.

  • Entrada Therapeutics' Change in Accured Expenses rose 2296.81% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year decrease of 4699.12%. This contributed to the annual value of $1.7 million for FY2024, which is 5519.41% down from last year.
  • As of Q3 2025, Entrada Therapeutics' Change in Accured Expenses stood at $3.7 million, which was up 2296.81% from $4.3 million recorded in Q2 2025.
  • Over the past 5 years, Entrada Therapeutics' Change in Accured Expenses peaked at $6.9 million during Q3 2022, and registered a low of -$5.5 million during Q1 2025.
  • For the 4-year period, Entrada Therapeutics' Change in Accured Expenses averaged around $658266.7, with its median value being $1.6 million (2024).
  • Over the last 5 years, Entrada Therapeutics' Change in Accured Expenses had its largest YoY gain of 36913.5% in 2023, and its largest YoY loss of 79559.23% in 2023.
  • Quarter analysis of 4 years shows Entrada Therapeutics' Change in Accured Expenses stood at -$4.3 million in 2022, then skyrocketed by 145.03% to $2.0 million in 2023, then crashed by 121.74% to -$425000.0 in 2024, then skyrocketed by 979.29% to $3.7 million in 2025.
  • Its Change in Accured Expenses stands at $3.7 million for Q3 2025, versus $4.3 million for Q2 2025 and -$5.5 million for Q1 2025.